Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$16.22
+0.5%
$12.89
$9.22
$21.00
$742.64M11.72 million shs1.41 million shs
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$18.71
-1.4%
$15.15
$8.89
$24.50
$824.63MN/A658,119 shs313,407 shs
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$10.73
+3.8%
$7.11
$4.61
$10.90
$219.17M1.81175,516 shs714,870 shs
SiBone stock logo
SIBN
SiBone
$16.62
+0.2%
$17.01
$11.70
$20.05
$715.71M0.91513,233 shs250,633 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
-0.43%+3.73%+24.25%+48.07%+26.99%
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
+3.49%+23.99%+35.60%+23.50%+1,896,999,900.00%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
+4.23%+7.71%+75.25%+84.64%+59.32%
SiBone stock logo
SIBN
SiBone
+1.04%+6.76%-5.74%-12.59%+0.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AxoGen, Inc. stock logo
AXGN
AxoGen
2.6191 of 5 stars
3.52.00.00.03.21.70.6
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
1.5505 of 5 stars
3.40.00.00.02.50.80.0
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
2.5689 of 5 stars
1.05.00.00.02.54.21.9
SiBone stock logo
SIBN
SiBone
4.2558 of 5 stars
3.54.00.03.31.92.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AxoGen, Inc. stock logo
AXGN
AxoGen
3.00
Buy$26.0060.30% Upside
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
2.75
Moderate Buy$22.5620.55% Upside
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
4.00
Strong Buy$12.5016.50% Upside
SiBone stock logo
SIBN
SiBone
3.00
Buy$23.6742.40% Upside

Current Analyst Ratings Breakdown

Latest INFU, BBNX, AXGN, and SIBN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2025
SiBone stock logo
SIBN
SiBone
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$25.00
8/5/2025
SiBone stock logo
SIBN
SiBone
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00
7/30/2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$18.00 ➝ $21.00
7/30/2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetNeutral ➝ Neutral$15.00 ➝ $17.00
7/22/2025
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
7/21/2025
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/16/2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$26.00
6/12/2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$30.00
5/30/2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$16.00
5/30/2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$20.00
(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AxoGen, Inc. stock logo
AXGN
AxoGen
$187.34M3.98N/AN/A$2.44 per share6.65
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$65.12M12.49N/AN/A$6.94 per share2.70
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$139.89M1.57$0.84 per share12.79$2.47 per share4.34
SiBone stock logo
SIBN
SiBone
$167.18M4.29N/AN/A$3.95 per share4.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AxoGen, Inc. stock logo
AXGN
AxoGen
-$9.96M-$0.10N/AN/AN/A-2.29%-4.43%-2.34%11/6/2025 (Estimated)
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
-$54.76MN/A0.00N/AN/AN/AN/AN/A
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$870K$0.23178.8634.61N/A1.12%2.78%1.41%N/A
SiBone stock logo
SIBN
SiBone
-$30.91M-$0.56N/AN/AN/A-12.83%-14.20%-10.38%11/11/2025 (Estimated)

Latest INFU, BBNX, AXGN, and SIBN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
SiBone stock logo
SIBN
SiBone
-$0.19-$0.14+$0.05-$0.14$48.12 million$48.63 million
7/29/2025Q2 2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
-$0.51-$0.39+$0.12-$0.39$19.73 million$23.24 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AxoGen, Inc. stock logo
AXGN
AxoGen
N/AN/AN/AN/AN/A
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/AN/AN/AN/AN/A
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
N/AN/AN/AN/AN/A
SiBone stock logo
SIBN
SiBone
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AxoGen, Inc. stock logo
AXGN
AxoGen
0.59
4.14
2.67
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/A
14.68
13.79
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
0.50
1.98
1.59
SiBone stock logo
SIBN
SiBone
0.21
8.38
7.00

Institutional Ownership

CompanyInstitutional Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
80.29%
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/A
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
71.13%
SiBone stock logo
SIBN
SiBone
98.11%

Insider Ownership

CompanyInsider Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
2.78%
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/A
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
11.40%
SiBone stock logo
SIBN
SiBone
4.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
AxoGen, Inc. stock logo
AXGN
AxoGen
45046.01 million44.73 millionOptionable
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
29443.47 millionN/AN/A
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
41020.43 million19.10 millionOptionable
SiBone stock logo
SIBN
SiBone
35043.14 million41.42 millionOptionable

Recent News About These Companies

AlphaQuest LLC Purchases 25,764 Shares of SiBone $SIBN
SiBone (NASDAQ:SIBN) SVP Sells $52,065.56 in Stock
SI-BONE, Inc. (SIBN) Q2 2025 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AxoGen stock logo

AxoGen NASDAQ:AXGN

$16.22 +0.08 (+0.50%)
Closing price 04:00 PM Eastern
Extended Trading
$16.08 -0.14 (-0.86%)
As of 06:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Beta Bionics stock logo

Beta Bionics NASDAQ:BBNX

$18.71 -0.26 (-1.37%)
As of 04:00 PM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

InfuSystem stock logo

InfuSystem NYSE:INFU

$10.73 +0.39 (+3.77%)
Closing price 04:00 PM Eastern
Extended Trading
$10.93 +0.20 (+1.86%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

SiBone stock logo

SiBone NASDAQ:SIBN

$16.62 +0.03 (+0.18%)
Closing price 04:00 PM Eastern
Extended Trading
$16.62 0.00 (0.00%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.